By Mais Faraj
Clinical
July 12, 2016

Multistate Outbreak of Burkholderia cepacia Infections

Recommendations
CDC continues to work with FDA, health departments and multiple healthcare facilities to investigate a multi-state outbreak of infections caused by Burkholderia cepacia complex (also known as “B. cepaciacomplex”). At this time, CDC continues to recommend that clinicians not use any liquid docusate product as a stool softener or for any other medical purpose. This recommendation is now expanded to all patient populations. If an oral liquid docusate stool softener is medically necessary, alternative medicines should be used.
CDC urges healthcare providers and laboratories to remain on alert for infections caused by B. cepacia  complex occurring among non-cystic fibrosis (CF) patients and should inform infection prevention staff immediately when these infections are identified. In addition, although infections caused by B. cepacia complex are known to occur among patients with CF, any clusters of such infections should be reported. Cases and clusters should be reported to state or local public health authorities. 
Facilities that identify infections caused by B. cepacia complex among non-CF patients or clusters of these  infections among CF patients should sequester and save all docusate products used in the facility.‎‎
Investigation Update
To date, 47 B. cepacia complex cases have been confirmed by molecular typing to match one of two outbreak strain types identified from healthcare facilities in five states.  Reports of possible cases from additional states are currently being investigated. CDC has confirmed that two samples of unused oral liquid docusate product received from one of the affected hospitals have tested positive for B. cepaciacomplex. Further testing is being conducted to determine if bacteria from these samples match the outbreak strains.  FDA is currently testing multiple liquid docusate products that are epidemiologically linked to reported B. cepacia complex cases. To date, CDC has confirmed one product as having B. cepacia  complex growth; however, because of epidemiologic links, CDC is concerned about potential contamination of multiple liquid docusate products, pending FDA’s ongoing investigation of shared ingredients in the products in question.
CDC will provide an update to this announcement by July 14, 2016. Please direct questions to haioutbreak@cdc.gov. Members of the media should contact the CDC Media Office at media@cdc.gov.

Author Description

Mais Faraj

Mais is a clinical pharmacist at Superior Care Pharmacy.

Stay Informed

Sign up to receive the latest news about SCRx services, the industry and more.

Contact Us

Call us with your questions
619.785.3993